In:
Journal of the American Veterinary Medical Association, American Veterinary Medical Association (AVMA), Vol. 229, No. 4 ( 2006-08-15), p. 542-548
Abstract:
Objective —To determine outcome for dogs with nonresectable thyroid carcinomas treated with sodium iodide I 131 and identify factors associated with outcome. Design —Retrospective case series. Animals —39 dogs. Procedures —A definitive or presumptive diagnosis of thyroid tumor was made on the basis of cytologic or histologic examination, abnormal accumulation of sodium pertechnetate Tc 99m during scintigraphy, or both, and dogs were treated with sodium iodide I 131. Dogs with cervical thyroid tumors were evaluated 3 to 6 weeks after 131 I therapy, and residual tumor was resected when feasible. Results —Prior to 131 I therapy, 32 dogs had a solitary mass and 7 had metastases; 21 were hyperthyroid, 16 were euthyroid, and 2 were hypothyroid. Median survival time for dogs with local or regional tumors (ie, stage II or III) was significantly longer (839 days) than median survival time for dogs with metastasis (366 days). Tumor site (cervical vs ectopic), dose of sodium iodide I 131, age, body weight, treatment ( 131 I therapy alone vs 131 I therapy followed by surgery), and serum T 4 concentration prior to 131 I therapy were not significantly associated with survival time. Three dogs died of radioiodine-associated myelosuppression within 3 months after treatment, but no specific factor associated with development of toxicosis was identified. Conclusions and Clinical Relevance —Results suggested that 131 I therapy may result in prolonged survival times in dogs with nonresectable thyroid tumors, regardless of serum thyroxine concentration prior to treatment. Dogs undergoing 131 I therapy should be monitored for signs of bone marrow suppression.
Type of Medium:
Online Resource
ISSN:
0003-1488
DOI:
10.2460/javma.229.4.542
Language:
Unknown
Publisher:
American Veterinary Medical Association (AVMA)
Publication Date:
2006
detail.hit.zdb_id:
2904887-4
SSG:
22
Permalink